← Back to Search

Unknown

IRL201104 for Eosinophilic Esophagitis

Phase 2
Waitlist Available
Research Sponsored by Revolo Biotherapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

This study is evaluating whether a drug called IRL201104 can help treat people with eosinophilic esophagitis.

Eligible Conditions
  • Eosinophilic Esophagitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in the peak esophageal intraepithelial eosinophil count at Week 4.
Secondary outcome measures
Absolute change in Dysphagia Symptom Questionnaire (DSQ) score from baseline. The DSQ is used to measure the frequency and intensity of dysphagia. The DSQ scores can range from 0 to 84, with a lower score indicating less frequent or less severe dysphagia
Proportion of participants achieving peak esophageal intraepithelial eosinophil count of < 15 eos/hpf
Safety Laboratory Data: Biochemistry
+6 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 2: IRL201104 Dose BExperimental Treatment1 Intervention
IRL201104 IV on Days 0, 7, and 14
Group II: Arm 1: IRL201104 Dose AExperimental Treatment1 Intervention
IRL201104 IV on Days 0, 7, and 14
Group III: Arm 3: PlaceboPlacebo Group1 Intervention
Placebo IV on Days 0, 7, and 14
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IRL201104
2021
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

Revolo BiotherapeuticsLead Sponsor
3 Previous Clinical Trials
105 Total Patients Enrolled
Jeff Myers, MD, PhDStudy DirectorChief Medical Officer, Revolo Biotherapeutics
1 Previous Clinical Trials
63 Total Patients Enrolled
Michael Weinreich, MD, PhDStudy DirectorSenior Director, Revolo Biotherapeutics
1 Previous Clinical Trials
63 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What site did they apply to?
Revolo Investigational Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
2021. "A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05084963.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top